N-[4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]butyl]-1,3-benzothiazol-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-[4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]butyl]-1,3-benzothiazol-2-amine
• 化学式: C₁₉H₂₃FN₆S
• 分子量: 386.5
• InChiKey: ZARIXUKMKDHMSK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  85.4
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands
  申请人：Neurogen Corporation

  公开号：US20020058666A1

  公开（公告）日：2002-05-16

  Disclosed are compounds of the formula: 1 or pharmaceutically acceptable salts thereof, wherein: A is (un)substituted alkylene; R 1 and R 2 are the same or different and represent hydrogen, halogen, alkyl, alkoxy, alkylthio, hydroxy, (un)substitutedamino, cyano, nitro, sulfonamide, trifluoromethyl or trifluoromethoxy; R 3 , R 4 , R 5 , R 6 , and R 8 are independently hydrogen or alkyl; and X is sulfur, oxygen or NR 7 where R 8 is defined herein; m is an integer chosen from 0, 1 or 2; and Ar is an aryl or heteroaryl group as further defined herein, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.

  本发明公开了以下式子的化合物 1 或其药学上可接受的盐，其中 A 是（未）取代的亚烷基； R 1 和 R 2 相同或不同，代表氢、卤素、烷基、烷氧基、烷硫基、羟基、（未）取代氨基、氰基、硝基、磺酰胺、三氟甲基或三氟甲氧基； R 3 , R 4 , R 5 , R 6 和 R 8 独立地为氢或烷基；以及 X 是硫、氧或 NR 7 其中 R 8 在此定义； m 是选自 0、1 或 2 的整数；以及 Ar 是本文进一步定义的芳基或杂芳基、 这些化合物可用于治疗和/或预防神经心理障碍，包括但不限于精神分裂症、躁狂症、痴呆症、抑郁症、焦虑症、强迫行为、药物滥用、帕金森样运动障碍以及与使用神经安定剂有关的运动障碍。
• 2-PIPERAZINO ALKYLAMINO BENZOAZOLE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS
  申请人：NEUROGEN CORPORATION

  公开号：EP1117663A2

  公开（公告）日：2001-07-25
• US6284759B1
  申请人：——

  公开号：US6284759B1

  公开（公告）日：2001-09-04
• US6432958B1
  申请人：——

  公开号：US6432958B1

  公开（公告）日：2002-08-13
• [EN] 2-PIPERAZINO ALKYLAMINO BENZOAZOLE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS<br/>[FR] DERIVES DE 2-PIPERAZINO -ALKYL- AMINOBENZOAZOLE: LIGANDS SPECIFIQUES DU SOUS-TYPE DU RECEPTEUR DE LA DOPAMINE
  申请人：NEUROGEN CORP

  公开号：WO2000018767A2

  公开（公告）日：2000-04-06

  Disclosed are compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein: A is (un)substituted alkylene; R1 and R2 are the same or different and represent hydrogen, halogen, alkyl, alkoxy, alkylthio, hydroxy, (un)substituted amino, cyano, nitro, sulfonamide, trifluoromethyl or trifluoromethoxy; R3, R4, R5, R6 and R8 are independently hydrogen or alkyl; and X is sulfur, oxygen or NR7 where R8 is defined herein; m is an integer chosen from 0, 1 or 2; and Ar is an aryl or heteroaryl group as further defined herein, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.